✦ LIBER ✦

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

✍ Scribed by Robert Chapman; Loretta Itri; Richard Gralla; David Kelsen; Ephraim Casper; Robert Golbey

Publisher: Springer
Year: 1982
Tongue: English
Weight: 238 KB
Volume: 7
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254550

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of oral VP-16-213 in smal

Phase II study of oral VP-16-213 in small cell lung cancer

✍ Yasaku Matsui; Shunsaku Oshima; Masao Kado; Masahiko Nakayama; Kaoru Shimokata; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 1 views

Cis-dichlorodiammineplatinum (II) and VP

Cis-dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non-small cell lung cancer

✍ Goldhirsch, Aron ;Joss, Rudolf A. ;Cavalli, Franco ;Sonntag, Roland W. ;Brunner, 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

## Abstract Twenty‐three patients with non‐small cell lung cancer were treated with a combination of cis‐dichlorodiammineplatinum(II) 100 mg/m^2^ IV on day 1 and VP 16–213 80 mg/m^2^ IV on days 1–3. Eighteen patients are evaluable for response. Seven partial remissions with a median duration of 3 m

Phase II trial of vindesine and VP16-213

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR

Phase II trial of edatrexate in small ce

Phase II trial of edatrexate in small cell lung cancer

✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Cisplatin and etoposide (VP-16) as a sin

Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial

✍ Corrado Boni; Giorgio Cocconi; Giancarlo Bisagni; Guido Ceci; Giuseppe Peracchia 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB 👁 2 views

Doxorubicin, cyclophosphamide and VP16-2

Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer

✍ Joseph Aisner; Margaret Whitacre; David A. VanEcho; Margaret Wesley; Peter H. Wi 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 742 KB

Small cell lung cancer requires aggressive combination chemotherapy. The three active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 mg/m2 i.v. day 1 and VP16-213 (E) 50 mg/m2/day i.v. days 1-5 were given together. The combination (ACE) was given every 21 days without chest ir